EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Efficacy of Lumateperone 42 mg in Major Depressive Disorder

Suresh Durgam, Willie R Earley, Raffaele Migliore, Hassan Lakkis, Roger S McIntyre, Maurizio Fava

The Primary Care Companion For CNS Disorders · 03.11.2026 · 28 (6)

DOI: 10.4088/pcc.26m04289 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Primary Care Companion For CNS Disorders, online erschienen am 03.11.2026. Verfasst von Suresh Durgam und 5 weiteren Autor:innen. Beteiligte Einrichtung: Former employee of Intra-Cellular Therapies, a Johnson & Johnson company, Bedminster, New Jersey. Hauptthemen laut MEDLINE: Antidepressive Agents, Antipsychotic Agents, Heterocyclic Compounds, 4 or More Rings, Major Depressive Disorder.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antidepressive AgentsAntipsychotic AgentsHeterocyclic Compounds, 4 or More RingsMajor Depressive DisorderAdultAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodDrug Therapy, CombinationPsychiatric Status Rating Scales

Substanzen

Antidepressive AgentsAntipsychotic AgentsHeterocyclic Compounds, 4 or More Ringslumateperone

Autor:innen und Institutionen

  • Former employee of Intra-Cellular Therapies, a Johnson & Johnson company, Bedminster, New Jersey.
  • Corresponding Author: Suresh Durgam, MD, former employee of Intra-Cellular Therapies, a Johnson & Johnson company, 135 US Highway 202/206, Ste 6, Bedminster, NJ 07921 (sdpsychiatry@avanagroup.com).
  • Intra-Cellular Therapies, a Johnson & Johnson company, Bedminster, New Jersey.
  • Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.

Zitieren

APA

Durgam, S., Earley, W. R., Migliore, R., Lakkis, H., McIntyre, R. S., & Fava, M. (2026). Efficacy of Lumateperone 42 mg in Major Depressive Disorder. The Primary Care Companion For CNS Disorders, 28(6). https://doi.org/10.4088/pcc.26m04289

Vancouver

Durgam S, Earley WR, Migliore R, Lakkis H, McIntyre RS, Fava M. Efficacy of Lumateperone 42 mg in Major Depressive Disorder. The Primary Care Companion For CNS Disorders. 2026;28(6). doi:10.4088/pcc.26m04289

BibTeX
@article{Durgam2026,
  author = {Durgam, Suresh and Earley, Willie R and Migliore, Raffaele and Lakkis, Hassan and McIntyre, Roger S and Fava, Maurizio},
  title = {Efficacy of Lumateperone 42 mg in Major Depressive Disorder},
  journal = {The Primary Care Companion For CNS Disorders},
  year = {2026},
  volume = {28},
  number = {6},
  doi = {10.4088/pcc.26m04289}
}
Kostenlos starten →